Holen Sie sich die Stockscreener-App
30.56
8.56%
2.41
Schlusskurs vom Vortag:
$28.15
Offen:
$29.5
24-Stunden-Volumen:
43.27M
Relative Volume:
1.15
Marktkapitalisierung:
$6.97B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
58.53
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+6.04%
1M Leistung:
+43.21%
6M Leistung:
-37.35%
1J Leistung:
+8.60%
1-Tages-Spanne:
$28.90
$31.33
1-Wochen-Bereich:
$27.03
$31.86
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
30.56 | 6.42B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.63 | 52.60B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.87 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.58 | 42.40B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 36.34B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
567.16 | 25.11B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health Inc (HIMS) Shares Surge 8.6% -- What GF Score of 81 Tells Investors - GuruFocus
Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot - TechStock²
Why Is Hims & Hers Health (HIMS) Stock Soaring Today - The Globe and Mail
HIMS Stock Rises as Options Activity Surges - GuruFocus
Hims and Hers Expands Its Technology-Driven Consumer Health Platform - MSN
HIMS Stock Rises as J.P. Morgan Initiates Coverage with Overweig - GuruFocus
HIMS Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
How Expanding GLP‑1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story - Yahoo Finance
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims - Yahoo Finance
Hims rises as J.P. Morgan initiates at Overweight on rich catalyst path - Seeking Alpha
Hims & Hers (HIMS) Bets Big on Branded GLP-1s — J.P. Morgan Likes What It Sees - CoinCentral
HIMS Maintains Rating by B of A Securities -- Price Target Raised to $32 - GuruFocus
Hims & Hers Health (NYSE:HIMS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path - Stocktwits
JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook - Investing.com India
Dan Kenger Hims & Hers The Orange Pill Bottle Is Out And A Whole New Kind Of Healthcare Brand Is In - BuzzFeed
HIMS plunges 51.2% in 6 months: Should you still hold the stock or sell? - MSN
HIMS stock pares losses after-hours: Citi flags 'big caveat' in Amazon's GLP-1 push that limits risk to Hims model - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Hims & Hers Health - The National Law Review
Hims & Hers Health (HIMS) soars 11.1%: Is further upside left in the stock? - MSN
Hims stock falls as GLP-1 shift raises questions on strategy - TradingView
Hims Stock Falls on Pivot From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing. - Barron's
Hims stock price reacts strongly to crucial FDA review - thestreet.com
Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership - GuruFocus
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch - Benzinga
Hims & Hers Health (NYSE:HIMS) Shares Gap UpWhat's Next? - MarketBeat
Hims & Hers (HIMS) Stock Surges 7% on Eli Lilly Weight Loss Drug Partnership Expansion - Blockonomi
Hims & Hers (HIMS) Stock Jumps 7% After Expanding Eli Lilly GLP-1 Deal - CoinCentral
AI for investors - MLQ.ai
+1.37% for Hims & Hers Health stock as Novo Nordisk Wegovy collaboration adds branded therapies - Traders Union
BofA raises Hims and Hers stock price target on Lilly partnership - Investing.com Canada
LLY Sees Surge as Hims & Hers Expands Prescription Capabilities - GuruFocus
Hims & Hers jumps 7% after expanding partnership with Eli Lilly - Yahoo Finance
Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days - Stocktwits
Hims & Hers Health Legal Chief Sells Shares Worth Over $280000 - Koran Manado
Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com Canada
Full Range of FDA-Approved GLP-1s Available on Hims & Hers - Hims & Hers Newsroom
Hims & Hers builds scalable data-driven personalized care platform - MSN
Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in? - TipRanks
HIMS Stock Slides Premarket: Rival Telehealth Firm Ro Launches Aggressive Price Cuts In GLP-1 Subscription Fight - Stocktwits
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 9,463 Shares - MarketBeat
Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock - Investing.com Canada
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock - Investing.com
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock By Investing.com - Investing.com Canada
Hims & Hers (HIMS) legal chief sells 9,463 shares in planned trade - Stock Titan
Hims & Hers (NYSE: HIMS) CFO option exercises and pre-planned share sale - Stock Titan
HIMS Expands Offerings for Menopause with Estrogen Patches - GuruFocus
Hims & Hers offers estrogen patches as US demand surges - USA Today
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):